Biotech Values

[drbio45]

from the Paion data

Ten of the 14 deaths in the 125 mcg/kg dose group were considered by the investigators as not related to the drug, 9 of which occurred 14 or more days after stroke and were from non-neurological causes.

It seems to me that with 10 deaths not related to the drug for non neurological causes it would have been pretty damn hard to get a good outcome because all these patients were consider total failures because the died.

forest did a 186 patient trial. sound cheap to me

look what they are doing with cypb. first trial failed with 880 patients. so they increase next trial to 1200. the 3rd phase 3 has 800 patients. why not do another 1200 patient trial. It doesn't make sense

the three drugs they got approved were done before they got cheap